Copyright ©The Author(s) 2023.
World J Stem Cells. May 26, 2023; 15(5): 302-322
Published online May 26, 2023. doi: 10.4252/wjsc.v15.i5.302
Table 1 Clinical trials that utilize the products of described genes as drug components or targets
Trial number and phase
Intervention details
BMP4hrBMP4GlioblastomaNCT02869243 (phase I)Delivery of human recombinant BMP4
GRIN2BEVT 101Healthy volunteers (brain function assessment)NCT00526968 (phase I)Delivery of selective GRIN2B antagonist
RRM2COH29Solid tumorsNCT02112565 (phase I)Delivery of ribonucleotide reductase inhibitor
WT1DSP-7888Gliomas (incl. GBM)NCT02750891 (phase I/II)Delivery of WT1 peptide-based cancer vaccine
KIF20AKIF20A peptideSmall cell lung cancerNCT01069653 (phase I)Delivery of KIF20A peptide-based vaccination
NF2IAG933Solid tumorsNCT04857372 (phase I)Not yet disclosed (the drug presumably counteracts the YAP/TAZ hyperactivity that occur following NF2 loss)
RXRG9-cis retinoic acidBreast cancerNCT00001504 (phase I)Delivery of RXRG ligand